feedback

Course Director

Jonathan Corren, MD
Jonathan Corren, MD

David Geffen School of Medicine at UCLA
Los Angeles, California

Faculty

Paul Yamauchi
Paul Yamauchi, MD

David Geffen School of Medicine at UCLA
Harbor-UCLA Medical Center
John Wayne Cancer Institute
Dermatology Institute & Skin Care Center, Inc.
Clinical Science Institute
Santa Monica, California

Accredited by

Medical Learning Institute, Inc.

Activity Details

Credit Types:CME / MOC / CNE / CPE
Credit Amount:0.75 Credits
Release Date:2019-Apr-12
Expiration Date:2020-Apr-11
Estimated Time for Completion:45 minutes
Registration Required:No
Cost:Free of Charge
Expert commentary is based on data presented at the 2019 American Academy of Dermatology (AAD) Annual Meeting and 2019 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting.*
*PeerView is an independent publisher of conference news and medical education programs.

Activity Description and Educational Objectives

In this activity, experts in allergy and dermatology discuss advances in the management of allergic and inflammatory diseases presented at the 2019 American Academy of Dermatology Annual Meeting and the American Academy of Allergy, Asthma & Immunology 2019 Annual Meeting.

Upon completion of this activity, participants will be able to:
  • Describe the relationship between type 2 inflammatory disorders, including atopic dermatitis, asthma, chronic rhinosinusitis and nasal polyps (CRS/NP), and eosinophilic esophagitis (EoE)
  • Discuss emerging data related to the efficacy and safety of therapies for the treatment of allergic and inflammatory diseases
  • Apply the latest clinical data to the treatment of patients with allergic and inflammatory disorders, such as atopic dermatitis, asthma, CRS/NP, and EoE

Target Audience

This activity has been designed to meet the educational needs of allergists/immunologists, dermatologists, pulmonologists, nurses, pharmacists, and other clinicians involved in the management of patients with allergic and inflammatory diseases.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. A score of 70% or higher is needed to obtain CME/MOC/CNE/CPE credit. There are no pre-requisites and there is no fee to participate in this activity or to receive CME/MOC/CNE/CPE credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: April 12, 2019 - April 11, 2020
Time to Complete: 45 minutes

Faculty and Disclosure / Conflict of Interest Policy

Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by Medical Learning Institute, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

Other PVI associates who are in a position to have control over the content of this activity, do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME/MOC/CNE/CPE activity during the past 12 months.

The associates of the Medical Learning Institute, Inc., the accredited provider for this activity, do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME/MOC/CNE/CPE activity during the past 12 months.

Course Directors

Jonathan Corren, MD
Associate Clinical Professor of Medicine and Pediatrics
David Geffen School of Medicine at UCLA
Los Angeles, California

Jonathan Corren, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Equillium, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd.; MedImmune; Regeneron Pharmaceuticals, Inc.; and sanofi-aventis U.S. LLC.
Grant/Research Support from AstraZeneca; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Regeneron Pharmaceuticals, Inc.; and sanofi-aventis U.S. LLC.
Speakers Bureau participant with AstraZeneca; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Regeneron Pharmaceuticals, Inc.; and sanofi-aventis U.S. LLC.

Jonathan Corren, MD, does not intend to discuss any non-FDA-approved or investigational use of any products/devices.

Paul Yamauchi, MD
Clinical Assistant Professor of Dermatology David Geffen School of Medicine at UCLA
Harbor-UCLA Medical Center Division of Dermatology
Adjunct Associate Professor John Wayne Cancer Institute
Dermatology Institute & Skin Care Center, Inc.
Clinical Science Institute
Santa Monica, California

Paul Yamauchi, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Amgen Inc.; Celgene Corporation; Dermira, Inc.; Janssen Pharmaceuticals, Inc.; LEO Pharma Inc.; Lilly ICOS LLC; Menlo Therapeutics; Novartis Pharmaceuticals Corporation; Ortho Dermatologics, Inc.; Pfizer Inc.; Regeneron; Sun Pharmaceutical Industries Ltd.; and UCB, Inc.
Grant/Research Support from Amgen Inc.; Celgene Corporation; Dermira, Inc.; Galderma Laboratories, L.P.; Janssen Pharmaceuticals, Inc.; LEO Pharma Inc.; Lilly ICOS LLC; MedImmune; Menlo Therapeutics; Novartis Pharmaceuticals Corporation; Ortho Dermatologics, Inc.; Pfizer Inc.; Regeneron; Sandoz AG; and UCB, Inc. (All research support to institution.)
Speakers Bureau participant with AbbVie Inc.; Amgen Inc.; Celgene Corporation; Dermira, Inc.; Janssen Pharmaceuticals, Inc.; LEO Pharma Inc.; Lilly ICOS LLC; Novartis Pharmaceuticals Corporation; Ortho Dermatologics, Inc.; Pfizer Inc.; Regeneron; sanofi-aventis U.S. LLC; Sun Pharmaceutical Industries Ltd.; and UCB, Inc.
Other Financial or Material Support from Medical Board National Psoriasis Foundation.

Paul Yamauchi, MD, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: the use of dupilumab in a pediatric population with atopic dermatitis.

Content Reviewers

Norman L. Koven, MD, has no financial interests/relationships or affiliations in relation to this activity.

Tracy L. Greene, MSN, RN, FNP-C, Lead Nurse Planner, has no financial interests/relationships or affiliations in relation to this activity.

Bobbie Perrin, RN, OCN, has no financial interests/relationships or affiliations in relation to this activity.

Teresa Haile, RPh, MBA, Lead Pharmacy Planner, has no financial interests/relationships or affiliations in relation to this activity.

Shelley Chun, PharmD, has no financial interests/relationships or affiliations in relation to this activity.

Medical Director

Mary Mihalovic
PVI, PeerView Institute for Medical Education

Mary Mihalovic has no financial interests/relationships or affiliations in relation to this activity.

Disclaimer

The information provided at this CME/MOC/CNE/CPE activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition. Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.

Providership, Credit, and Support

Physicians

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Learning Institute, Inc. designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOCSuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Participation information will be shared with ABIM through the ACCME’s Program and Activity Reporting System (PARS). Blinded individual or aggregated participant data may be shared with the funder of the activity.

Nurses

Medical Learning Institute, Inc. is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
Successful completion of this continuing nursing education activity will be awarded 0.75 contact hour(s).

Pharmacists

ACPEThe Medical Learning Institute, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Completion of this knowledge-based activity provides for 0.75 contact hours (0.075 CEUs) of continuing pharmacy education credit. The Universal Activity Number for this activity is 0468-9999-19-002-H01-P.

Providership


This CME/MOC/CNE/CPE activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.

Support

This educational activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

About This CME/MOC/CNE/CPE Activity

PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Medical Learning Institute, Inc.

Copyright © 2000-2019, PeerView

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.